Enzolytics Inc (ENZC)

[southswell7]

MORE MONSTER TIES FOR FOLKS THAT DIG LIKE ME:

Charles Cotropia, CEO and co-founder of BioClonetics Immunotherapeutics

"Our anti-HIV monoclonal antibody is one of only a few that target the HIV virus at a site that does not mutate. While other antibodies being examined have initial efficacy, most target a site that on the virus that changes with time. In other words, the virus structure changes so that the antibody is no longer effective. This ability of a virus to mutate is not new news — the flu virus and all others, do it every year. Otherwise there would be no need to re-engineer the flu virus each year."

Use of a monoclonal antibody to treat the HIV virus offers another unvoiced benefit.

Use of monoclonal antibodies would not require lifelong treatment but would be effective if administered for a limited time. And the antibody can be produced for pennies a dose. Thus, their impact on worldwide health could be remarkable.

Companies such as Genscript Labs, STC Biologics, Rapid Novor and Scripps Research have been most gracious in their willingness to work with us to move our technology forward.

DD Genscript labs folks. Holy shit! plus, look at some of the names:

Jon Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He joined BioCryst as President and CEO in January 2007. NASDAQ LISTED! The transformation that has taken place since then has advanced BioCryst to a company with its first product revenue and approvals, pivotal clinical programs and a diverse clinical pipeline, as well as the financial flexibility to build an enduring, successful biopharmaceutical company. Before joining BioCryst, he served as Senior Vice President of Corporate Development at MERCK KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company, which culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe.

George Church
Dr. George Church, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), co-author of 515 papers, 143 patent publications & the book "Regenesis". Dr. Church has developed methods used for the first genome sequence (1994) & million-fold cost reductions since (via fluor-NGS & nanopores), plus barcoding, DNA assembly from chips, genome editing, writing & recoding. He also co-initiated BRAIN Initiative (2011) & Genome Projects (GP-Read-1984, GP-Write-2016, PGP-2005: world's open-access personal precision medicine datasets); machine learning for protein engineering, tissue reprogramming, organoids, xeno-transplanation, in situ 3D DNA, RNA, protein imaging.

SOME OF THE LISTED COMPANIES WITH TIES Directly or Indirectly
BioCryst NASDAQ LISTED
Merck NYSE LISTED
GenScript LISTED IN HONG KONG WHO SPUN OFF NASDAQ LISTED LEGEND BioTECH $32

Read these pr's from just 1 of the Companies helping BioClonetics FORWARD! https://www.genscript.com/special/press-release

NOW, ADD IN WHAT Enzolytics HAS DEVELOPED!!